Plasma Lipidomic n-6 Polyunsaturated Fatty Acids and Type 2 Diabetes Risk in the EPIC-Potsdam Prospective Cohort Study
Authors' conclusion
Plasma n-6 PUFAs were associated differently with type 2 diabetes, depending on fatty acid and the lipid class.
Study context
- Population
- Participants of the EPIC-Potsdam cohort; subcohort 1,084 participants, 536 with incident T2Dsubcohort 1,084
- Exposure
- Plasma lipid class-specific n-6 PUFA concentrations and T2D risk
- Outcome
- Incident T2D
- Follow-up
- Median 6.5 years
Methodological detailsprospective, EPIC-Potsdam cohort
- Prospective
- EPIC-Potsdam cohort
Main finding
As reported in the abstract
T2D risk per 1 SD higher fatty acid concentration, by lipid class
- 18:2 in lysophosphatidylcholines, HR per 1 SD
- 0.53 (0.23-1.26) (95% CI)
- 18:2 in monoacylglycerols, HR
- 0.59 (0.38-0.92) (95% CI)
- 20:3 in phosphatidylcholines, HR
- 1.63 (1.23-2.14) (95% CI)
- 20:3 in phosphatidylethanolamines, HR
- 1.87 (1.32-2.65) (95% CI)
- 20:3 in phosphatidylinositol, HR
- 1.40 (1.05-1.87) (95% CI)
- 20:3 in free fatty acids, HR
- 1.44 (1.10-1.90) (95% CI)
- 20:3 in cholesteryl esters, HR
- 1.47 (1.09-1.98) (95% CI)
Observational data: associations, not effects.
Further findings
Genetic determinants of estimated D5D activity
- SNPs in D5D-encoding FADS genes explained relatively high proportions of variation of estimated D5D activity in those lipid classes
Original publication
Plasma Lipidomic n-6 Polyunsaturated Fatty Acids and Type 2 Diabetes Risk in the EPIC-Potsdam Prospective Cohort Study. Diabetes Care. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →